Translate to...

Biocon jumps 10%, hits 52-week high as DCGI approves use of Itolizumab on Covid-19 patients

Biocon jumps 10%, hits 52-week high as DCGI approves use of Itolizumab on Covid-19 patients

The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in India.